Cipla Ltd.'s consolidated net profit rose 49% year-on-year in the third quarter of the current financial year, beating analysts' estimates by a substantial margin.
The drugmaker posted a consolidated bottom line of Rs 1,571 crore in the quarter-ended December, according to an exchange filing on Tuesday. That compares with the Rs 1,208-crore consensus estimate of analysts tracked by Bloomberg.
The company's revenue climbed 7.1% year-on-year to Rs 7,073 crore, whereas the earnings before interest, taxes, depreciation and amortisation increased by 13.8% to Rs 1,989 crore. The Ebitda margin expanded to 28.1% from 26.5%.
Cipla also posted an exceptional loss of Rs 195 crore in the third quarter.
Cipla Q3 FY25 Highlights (Consolidated, YoY)
Revenue rises 7.1% to Rs 7,073 crore versus Rs 6,604 crore (Bloomberg estimate: Rs 6,967 crore).
Ebitda up 13.8% at Rs 1,989 crore versus Rs 1,748 crore (Estimate: Rs 1,777 crore).
Margin at 28.1% versus 26.5% (Estimate: 25.5%).
Profit up 48.7% at Rs 1,571 crore versus Rs 1,056 crore (Estimate: Rs 1,208 crore).
Cipla's 'One India' business, which covers branded prescription, trade generics and consumer health businesses, grew 10% YoY. The branded prescription business continued to outpace the market growth in key therapies, whereas the trade generics business is back on growth trajectory, the company said in a release.
Among key external markets, the business in North America delivered "quarterly revenue of $226 million supported by traction in differentiated assets", it added.
In "emerging markets and Europe", the company posted a revenue growth of 20% in US dollar terms, Cipla said.
The investments in research and development stood at Rs 360 crore, or 5.1% of sales, driven by product filings and development efforts, it added.
"We continue to make considerable progress across our focused markets. In Q3FY25, we delivered growth across all our various geographies, despite of a supply challenge in the US," said Umang Vohra, managing director and global chief executive officer of Cipla.
"Going ahead, the focus will be on growing our key markets, further building our flagship brands, investing in future pipeline as well as focusing on resolutions on the regulatory front," he added.
Shares of Cipla were trading 2.89% higher at Rs 1,436.25 apiece on the BSE, as compared to a 0.98% rise in the benchmark Sensex at 2:54 p.m.
Track live updates on Q3 earnings here.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
